Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Prelude Therapeutics Inc
PRLDCurrent price
1.06 USD
-0.09 USD (-7.83%)
Last closed
1.15 USD
Company
www.preludetx.com
ISIN
US74065P1012
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
65 491 892 USD
Yield for 12 month
-66.88 %
1Y
3Y
5Y
10Y
15Y
PRLD
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. Address: 175 Innovation Boulevard, Wilmington, DE, United States, 19805
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
5.4 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-1 169 000 USD
Last Year
-3 042 000 USD
Current Quarter
–
Last Quarter
-452 000 USD
Key Figures PRLD
1 year
3 years
5 years
10 years
EBITDA
-141 648 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-39.29 %
PEG Ratio
–
Return On Equity TTM
-66.64 %
Wall Street Target Price
5.4 USD
Revenue TTM
3 000 000 USD
Book Value
2.84 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-1.77 USD
Diluted Eps TTM
-1.77 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics PRLD
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PRLD
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation PRLD
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
21.8306
Enterprise Value EBITDA
-0.5402
Price Book MRQ
0.3592
Financials PRLD
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators PRLD
For 52 weeks
1.1 USD
6.8 USD
50 Day MA
2.45 USD
Shares Short Prior Month
2 486 117
200 Day MA
3.89 USD
Short Ratio
8.15
Shares Short
2 491 578
Short Percent
14.38 %
BeatStart